Zura Bio (ZURA)

• Market cap: $481M
• 1 day: -1.75%
• 5 days: -0.2%
• 1 month: 37.5%
• 3 months: -11.54%
• 6 months: -5.77%
• Year to date: -8.83%
• 1 year: 289.23%
• 5 years: -47.84%
• 10 years: -47.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Employees: 40